Clincosm LogoSign in Get a demo

Obesity

Showing NaN - NaN of 53
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Obesity, Overweight Trial in United States (LY3305677, Placebo)

Not yet recruiting
  • Obesity
  • Overweight
  • Mesa, Arizona
  • +27 more
Nov 21, 2023

Obesity, Overweight and Obesity Trial in United States (LY3305677, Placebo)

Not yet recruiting
  • Obesity
  • Overweight and Obesity
  • Mesa, Arizona
  • +23 more
Nov 6, 2023

Overweight, Obesity Trial in United States (Tirzepatide, Placebo)

Not yet recruiting
  • Overweight
  • Obesity
  • Pelham, Alabama
  • +19 more
Sep 14, 2023

Obesity Trial in United States (K-757 and K-833, K-757 and matching to K-833, Matching to K-757 and matching to K-833)

Not yet recruiting
  • Obesity
  • K-757 and K-833
  • +2 more
  • San Diego, California
  • +18 more
Aug 25, 2023

Obesity, Overweight Trial in Puerto Rico, United States (Tirzepatide, Semaglutide 2.4 mg)

Recruiting
  • Obesity
  • Overweight
  • Birmingham, Alabama
  • +31 more
Apr 26, 2023

Type 2 Diabetes, Obesity, Overweight or Obesity Trial in Worldwide (Orforglipron, Insulin Glargine)

Recruiting
  • Type 2 Diabetes
  • +5 more
  • Muscle Shoals, Alabama
  • +320 more
Apr 12, 2023

Obesity Trial in United States (Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and 2.0 mg, Semaglutide 2.4 mg

Completed
  • Obesity
  • Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
  • +3 more
  • Walnut Creek, California
  • +13 more
Jan 23, 2023

Overweight, Obesity and Diabetes, Type 2 Trial (Cagrilintide, Semaglutide, Placebo cagrilintide)

Not yet recruiting
  • Overweight
  • +2 more
  • Concord, California
  • +147 more
Jan 24, 2023

Obesity Trial in Worldwide (semaglutide 2.4 mg, semaglutide 2.4 mg ())

Active, not recruiting
  • Obesity
  • semaglutide 2.4 mg
  • semaglutide 2.4 mg (placebo)
  • Montgomery, Alabama
  • +64 more
Jan 24, 2023

Obesity, Overweight Trial in Worldwide (Tirzepatide, Placebo)

Recruiting
  • Obesity
  • Overweight
  • Gilbert, Arizona
  • +695 more
Jan 18, 2023

Overweight, Obesity Trial in Worldwide (Semaglutide, Placebo (semaglutide))

Active, not recruiting
  • Overweight
  • Obesity
  • Birmingham, Alabama
  • +804 more
Dec 19, 2022

Obesity Trial in Worldwide (Placebo, PF-06882961)

Active, not recruiting
  • Obesity
  • Anniston, Alabama
  • +40 more
Jun 29, 2022

Obesity Trial in Worldwide (Semaglutide, Placebo (semaglutide))

Active, not recruiting
  • Obesity
  • Fairhope, Alabama
  • +97 more
Jun 15, 2022

Overweight, Obesity Trial in Worldwide (Tirzepatide, Placebo)

Active, not recruiting
  • Overweight
  • Obesity
  • Pelham, Alabama
  • +119 more
Apr 12, 2022

Obesity Trial in United States (Multi-Modal Education (MME), Traditional Education (TE))

Active, not recruiting
  • Obesity
  • Multi-Modal Education (MME)
  • Traditional Education (TE)
  • Birmingham, Alabama
  • +7 more
Feb 11, 2022

Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (Semaglutide, Placebo)

Completed
Has Results
  • Metabolism and Nutrition Disorder
  • Obesity
  • Anniston, Alabama
  • +71 more
Jan 7, 2022

Adrenergic Cholinergic Enteric Measures/Mapping

Recruiting
  • Obesity
    • Louisville, Kentucky
      University of Louisville
    Dec 13, 2021

    Obesity, Overweight Trial in Worldwide (Semaglutide 1.0 mg, Semaglutide 2.4 mg, Placebo I (Semaglutide))

    Completed
    Has Results
    • Obesity
    • Overweight
    • Semaglutide 1.0 mg
    • +3 more
    • Buena Park, California
    • +146 more
    Nov 8, 2021

    Obesity, Overweight Trial in Worldwide (Tirzepatide, Placebo)

    Active, not recruiting
    • Obesity
    • Overweight
    • Pelham, Alabama
    • +69 more
    Oct 5, 2021

    ORBERA™ Post-Approval Study

    Completed
    • Obesity
    • Overweight
      • Little Rock, Arkansas
      • +10 more
      Jul 9, 2020

      Metabolism and Nutrition Disorder, Obesity Trial in Worldwide (Liraglutide 3.0 mg, Placebo)

      Completed
      Has Results
      • Metabolism and Nutrition Disorder
      • Obesity
      • Liraglutide 3.0 mg
      • Placebo
      • Birmingham, Alabama
      • +53 more
      Mar 13, 2020

      Obesity, Overweight Trial in Worldwide (LIK066, Placebo)

      Completed
      Has Results
      • Obesity
      • Overweight
      • Anniston, Alabama
      • +82 more
      Jan 27, 2020

      Obesity Trial in Worldwide (JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3)

      Completed
      Has Results
      • Obesity
      • JNJ-64565111 Dose Level 1
      • +4 more
      • Phoenix, Arizona
      • +50 more
      Jan 14, 2020

      Cataract, Diabetes, Hypertension Trial in Louisville (Cataract surgery)

      Unknown status
      • Cataract
      • +4 more
      • Cataract surgery
      • Louisville, Kentucky
        Bennett and Bloom Eye Centers
      Aug 27, 2019

      Cardiovascular Disease, High Cardiovascular Risk, Obesity Trial in Worldwide (Lorcaserin HCl, Placebo)

      Completed
      Has Results
      • Cardiovascular Disease
      • +4 more
      • Lorcaserin hydrochloride
      • Placebo
      • Alexander City, Alabama
      • +498 more
      Jun 27, 2019